Acorda Therapeutics, Inc - Strategy, SWOT and Corporate Finance Report
Summary
Acorda Therapeutics, Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.
Key Highlights
Acorda Therapeutics, Inc. (Acorda or 'the company') is engaged in the identification, development and commercialization of novel therapies to treat neurological disorders. It is also engaged in the development and marketing of therapies to help restore function in persons with spinal cord injury, multiple sclerosis and related conditions of the central nervous system. The company also offers various pipeline products to neurological therapies including heart failure, migraine, Primary Sclerosing Cholangitis, MS, spinal cord injury and various other disorders. Acorda's product portfolio are marketed under Zanaflex, Ampyra or Fampyra (dalfampridine); Inbrija, BTT1023, and GGF2. It develops additional inhaled medicines for both systemic and pulmonary conditions. Acorda primarily operates in the US. The company is headquartered in Ardsley, New York, the US
Scope
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook